Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Status:
Terminated
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease.
Supportive evidence for the value of systemic therapy does not exist for this disease and
there are no agents currently approved by regulatory agencies. This study will evaluate the
drug Gilotrif in patients with metastatic progressive PSCC following chemotherapy. Gilotrif
has shown supportive evidence in non-small cell lung cancer by inhibiting certain proteins
that are also found in PSCC. The drug has the potential for some patients to exhibit a
response contributing to a greater quality of life.